Technical Analysis for ASND - Ascendis Pharma A/S

Grade Last Price % Change Price Change
grade D 103.72 -0.81% -0.85
ASND closed down 0.81 percent on Friday, September 13, 2019, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ASND trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
200 DMA Support Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
200 DMA Support Bullish -0.81%
Lower Bollinger Band Walk Weakness -0.81%

Older signals for ASND ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
ASND Chart by TradingView
Basic chart:
Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Biotechnology Life Sciences Disease Diabetes Hormones Pulmonary Arterial Hypertension Peptide Hormones Treatment Of Diabetes Breakthrough Therapy Genentech Recombinant Proteins Treprostinil
Is ASND a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 12 Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting
Sep 5 Ascendis Pharma (ASND) Presents At 2019 Wells Fargo Healthcare Conference - Slideshow
Sep 3 3 Biopharma Stocks With Over 50% Upside
Aug 29 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2019 Results - Earnings Call Transcript
Aug 29 Ascendis Pharma A/S Announces Three Investor Presentations in September
Aug 29 The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings
Aug 29 Edited Transcript of ASND earnings conference call or presentation 28-Aug-19 8:30pm GMT
Aug 29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript
Aug 28 Ascendis Pharma reports Q2 results
Aug 28 Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results
See more ASND news...
Indicators
Indicator Value
52 Week High 133.67
52 Week Low 53.205
Average Volume 218,484
200-Day Moving Average 101.6137
50-Day Moving Average 113.0902
20-Day Moving Average 110.822
10-Day Moving Average 107.64
Average True Range 4.4947
ADX 13.73
+DI 14.0209
-DI 24.6085
Chandelier Exit (Long, 3 ATRs ) 108.4159
Chandelier Exit (Short, 3 ATRs ) 113.6641
Upper Bollinger Band 118.8411
Lower Bollinger Band 102.8029
Percent B (%b) 0.06
BandWidth 14.472036
MACD Line -2.6412
MACD Signal Line -1.8876
MACD Histogram -0.7536
Fundamentals Value
Market Cap 3.37 Billion
Num Shares 32.5 Million
EPS -3.61
Price-to-Earnings (P/E) Ratio -28.73
Price-to-Sales 288.07
Price-to-Book 6.90
PEG Ratio -0.32
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 108.94
Resistance 3 (R3) 108.79 106.89 108.07
Resistance 2 (R2) 106.89 105.56 106.97 107.78
Resistance 1 (R1) 105.31 104.74 104.36 105.46 107.49
Pivot Point 103.41 103.41 102.94 103.49 103.41
Support 1 (S1) 101.83 102.08 100.88 101.98 99.95
Support 2 (S2) 99.93 101.26 100.01 99.66
Support 3 (S3) 98.35 99.93 99.37
Support 4 (S4) 98.50